During the public consultation phase of the review of MediShield Life last year, the Singapore Society of Oncology (SSO), a professional medical organisation consisting of doctors who treat and manage cancer patients, shared its views.
Among the issues raised was the high prices of new cancer drugs and the affordability of treatment. There was a suggestion to augment efforts in negotiating better prices with pharmaceutical companies for the financial sustainability of our national healthcare system.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
